
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings Inc. reported a robust financial performance with a significant year-over-year increase in gross profit, expanding by $2.2 million to reach $20.4 million while gross margin grew 260 basis points to 56.4%. The company's core oncology business achieved record quarterly revenue, further supported by a new contract with a large hospital system, which is anticipated to enhance patient volumes in the upcoming quarters. Additionally, net operating cash flow improved markedly to $17.3 million, reflecting a 38% increase due to higher earnings and improved working capital management, underscoring the company’s financial strength and operational efficiency.
Bears say
InfuSystems Holdings faces a significant reduction in anticipated annual revenue of $7.1 million in 2026 due to a restructured contract with its largest biomedical services customer, adding pressure to its financial outlook. Additionally, the company is experiencing margin compression and competitive challenges, alongside reduced sales rep productivity, which collectively hinder the potential for revenue growth. Cash flow from operations showed a decline of 10% year-over-year in Q4 2025, raising concerns about the sustainability of operational performance in the long term.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares